A Phase 3 interventional study of Faricimab and Aflibercept in Wet Macular Degeneration, sponsored by Hoffmann-La Roche. Completed at 161 sites in 15 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-07-23.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Wet Macular Degeneration with a site in United States — 7 open to participants now, 14 under way, 7 of them phase 3. Wet Macular Degeneration · United States.
Among the 49 studies in Wet Macular Degeneration with a site in United States, this one is the 7th largest by enrollment of the 45 interventional ones that give a count, is one of 10 that started in 2019, is one of 13 in phase 3, and was the 21st registered.
93 studies on the registry are indexed under Wet Macular Degeneration; 10 are open to participants now.
Browse Wet Macular Degeneration studies →7 of the 49 studies in Wet Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:
EyeBiotech Ltd. · Sites in United States, Brazil, Colombia and 6 more countries
Ages 50+
EyeBiotech Ltd. · Sites in United States, Argentina, Australia and 9 more countries
Ages 50+
4D Molecular Therapeutics · Sites in United States, Argentina, Australia and 14 more countries
Ages 50+
4D Molecular Therapeutics · Sites in United States, Puerto Rico
Ages 50+
University of Iowa · Sites in United States
Ages 50–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Wet Macular Degeneration studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 22 · Phase 3 19 · Phase 4 4
First in 2006; this study’s year is marked. 10 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 671 is above the median of 101 across 74 interventional studies indexed under Wet Macular Degeneration.
Median enrollment 91 across the 45 interventional studies, 22 across the 4 observational. Of the 33 that completed or were terminated, 19 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 49 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 2 studies filed under Wet Macular Degeneration — fewer than ten, so there is no comparison to draw.
6 of the studies in Wet Macular Degeneration with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04704921Phase 3AbbViePivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | 2026-12 |
| NCT06864988Phase 34D Molecular Therapeutics4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-06 |
| NCT07064759Phase 34D Molecular TherapeuticsSingle Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-11 |
| NCT04504123University of IowaMMP-9 Inhibition for Recalcitrant Wet AMD | 2026-12-31 |
| NCT051972704D Molecular Therapeutics4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration | 2027-03 |
Add all 6 to your calendar (.ics) → With an account.
Among the 49 studies in Wet Macular Degeneration with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Faricimab · Procedure: Sham Procedure
Drug: Aflibercept · Procedure: Sham Procedure
Faricimab will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.
Also known as: VABYSMO™, RO6867461, RG7716
Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).
Also known as: Eylea
The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥74, 73-55, and ≤54 letters), baseline LLD (\<33 and ≥33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% CI is a rounding of 95.03% CI.
Time frame: From Baseline through Week 48
Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥74, 73-55, and ≤54 letters), baseline LLD (\<33 and ≥33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% CI is a rounding of 95.03% CI.
Time frame: From Baseline through Week 60
Change From Baseline in BCVA in the Study Eye Over Time
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥74, 73-55, and ≤54 letters), baseline LLD (\<33 and ≥33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48
BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: Baseline, average of Weeks 40, 44, and 48
Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60
BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: Baseline, average of Weeks 52, 56, and 60
Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Over Time
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Percentage of Participants Gaining ≥10 Letters From the Baseline BCVA in the Study Eye Over Time
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Percentage of Participants Gaining ≥5 Letters From the Baseline BCVA in the Study Eye Over Time
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Percentage of Participants Gaining ≥0 Letters From the Baseline BCVA in the Study Eye Over Time
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: Baseline, average of Weeks 40, 44, and 48
Percentage of Participants Avoiding a Loss of ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: Baseline, average of Weeks 52, 56, and 60
Percentage of Participants Avoiding a Loss of ≥15 Letters From the Baseline BCVA in the Study Eye Over Time
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted percentage of participants avoiding a loss of letters in BCVA from baseline was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Percentage of Participants Avoiding a Loss of ≥10 Letters From the Baseline BCVA in the Study Eye Over Time
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted percentage of participants avoiding a loss of letters in BCVA from baseline was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Percentage of Participants Avoiding a Loss of ≥5 Letters From the Baseline BCVA in the Study Eye Over Time
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted percentage of participants avoiding a loss of letters in BCVA from baseline was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48
BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: Baseline, average of Weeks 40, 44, and 48
Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48
BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (\<69 letters vs. ≥69 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: Baseline, average of Weeks 40, 44, and 48
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (\<69 letters vs. ≥69 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48
BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: Baseline, average of Weeks 40, 44, and 48
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Percentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 48
Percentages are based on the number of participants randomized to the faricimab arm who have not discontinued the study at Week 48. The treatment interval at a given visit is defined as the treatment interval decision followed at that visit. The 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: Week 48
Percentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 60
Percentages are based on the number of participants randomized to the faricimab arm who have not discontinued the study at Week 60. The treatment interval at a given visit is defined as the treatment interval decision followed at that visit. The 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: Week 60
Percentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 112
Percentages are based on the number of participants randomized to the faricimab arm who have not discontinued the study at Week 112. Treatment interval at a given visit is defined as the treatment interval decision followed at that visit. Treatment interval at Week 112 is calculated using data recorded at Week 108. The 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: Weeks 108 and 112
Number of Study Drug Injections Received in the Study Eye Through Week 48
Time frame: From Baseline through Week 48
Number of Study Drug Injections Received in the Study Eye Through Week 60
Time frame: From Baseline through Week 60
Number of Study Drug Injections Received in the Study Eye Through Week 108
Time frame: From Baseline through Week 108
Change From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 40, 44, and 48
Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. For the Mixed Model of Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (\<33 letters and ≥33 letters), and region (U.S. and Canada, Asia, and the rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: From Baseline through Week 48
Change From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 52, 56, and 60
Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. For the Mixed Model of Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (\<33 letters and ≥33 letters), and region (U.S. and Canada, Asia, and the rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: From Baseline through Week 60
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time
Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. For the Mixed Model of Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (\<33 letters and ≥33 letters), and region (U.S. and Canada, Asia, and the rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye Over Time
Intraretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 millimetre \[mm\]). The weighted estimates of the percentage of participants with absence of intraretinal fluid were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 104, 108, and 112
Percentage of Participants With Absence of Subretinal Fluid in the Study Eye Over Time
Subretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants with absence of subretinal fluid were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 104, 108, and 112
Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye Over Time
Intraretinal fluid and subretinal fluid were measured using optical coherence tomography (OCT) in the central subfield (center 1 millimetre \[mm\]). The weighted estimates of the percentage of participants with absence of intraretinal and subretinal fluid were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 104, 108, and 112
Percentage of Participants With Absence of Pigment Epithelial Detachment in the Study Eye Over Time
Pigment epithelial detachment was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants with absence of pigment epithelial detachment were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 104, 108, and 112
Percentage of Participants With Absence of Intraretinal Cysts in the Study Eye Over Time
Time frame: Up to 112 weeks
Change From Baseline in Total Area of Choroidal Neovascularization Lesion in the Study Eye at Week 48
The total area of the choroidal neovascularization lesion in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.
Time frame: Baseline and Week 48
Change From Baseline in Total Area of Choroidal Neovascularization Lesion in the Study Eye at Week 112
The total area of the choroidal neovascularization lesion in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.
Time frame: Baseline and Week 112
Change From Baseline in Total Area of Choroidal Neovascularization Leakage in the Study Eye at Week 48
The total area of choroidal neovascularization leakage in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.
Time frame: Baseline and Week 48
Change From Baseline in Total Area of Choroidal Neovascularization Leakage in the Study Eye at Week 112
The total area of choroidal neovascularization leakage in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.
Time frame: Baseline and Week 112
Percentage of Participants With at Least One Adverse Event
This analysis of adverse events (AEs) includes both ocular and non-ocular (systemic) AEs. Multiple occurrences of the same AE in one individual are counted only once. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. AEs of special interest included the following: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law; Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).
Time frame: From first dose of study drug through end of study (up to 112 weeks)
Percentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye
This analysis of adverse events (AEs) only includes ocular AEs, which are categorized as having occurred either in the study eye or the fellow eye. Multiple occurrences of the same AE in one individual are counted only once. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. Ocular AEs of special interest included the following: Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).
Time frame: From first dose of study drug through end of study (up to 112 weeks)
Percentage of Participants With at Least One Non-Ocular Adverse Event
This analysis of adverse events (AEs) only includes non-ocular (systemic) AEs. Multiple occurrences of the same AE in one individual are counted only once. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. The non-ocular AE of special interest was: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.
Time frame: From first dose of study drug through end of study (up to 112 weeks)
Plasma Concentration of Faricimab Over Time
Faricimab concentration in plasma was determined using a validated immunoassay method.
Time frame: Pre-dose at Baseline, Weeks 4, 16, 20, 48, 76, and 112
Percentage of Participants Who Tested Positive for Treatment-Emergent Anti-Drug Antibodies Against Faricimab During the Study
Anti-drug antibodies (ADAs) against fariciamb were detected in plasma using a validated bridging enzyme-linked immunosorbent assay (ELISA). The percentage of participants with treatment-emergent ADA-positive samples includes post-baseline evaluable participants with at least one treatment-induced (defined as having an ADA-negative sample or missing sample at baseline and any positive post-baseline sample) or treatment-boosted (defined as having an ADA-positive sample at baseline and any positive post-baseline sample with a titer that is equal to or greater than 4-fold baseline titer) ADA-positive sample during the study treatment period.
Time frame: Pre-dose at Baseline, Weeks 4, 20, 48, 76, and 112
| Milestone | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Started | 334 | 337 |
| Received at least one dose of study drug | 333 | 336 |
| Completed up to week 48 | 319 | 323 |
| Completed | 274 | 291 |
| Not completed | 60 | 46 |
| Withdrew: Withdrawal by subject | 25 | 17 |
| Withdrew: Death | 13 | 7 |
| Withdrew: Lost to follow-up | 7 | 8 |
| Withdrew: Adverse event | 6 | 8 |
| Withdrew: Physician decision | 5 | 2 |
| Withdrew: Lack of efficacy | 2 | 0 |
| Withdrew: Other | 2 | 4 |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥74, 73-55, and ≤54 letters), baseline LLD (\<33 and ≥33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% CI is a rounding of 95.03% CI.
| ETDRS Letters | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48 | 5.8 (4.6 to 7.1) | 5.1 (3.9 to 6.4) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥74, 73-55, and ≤54 letters), baseline LLD (\<33 and ≥33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% CI is a rounding of 95.03% CI.
| ETDRS Letters | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60 | 5.4 (4.0 to 6.8) | 4.6 (3.3 to 6.0) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥74, 73-55, and ≤54 letters), baseline LLD (\<33 and ≥33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% CI is a rounding of 95.03% CI.
| ETDRS Letters | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Week 4 | 4.0 (3.2 to 4.8) | 3.6 (2.8 to 4.4) |
| Week 8 | 5.5 (4.6 to 6.4) | 4.5 (3.6 to 5.4) |
| Week 12 | 6.4 (5.5 to 7.4) | 5.3 (4.4 to 6.2) |
| Week 16 | 6.8 (5.8 to 7.8) | 5.2 (4.2 to 6.2) |
| Week 20 | 6.6 (5.5 to 7.6) | 4.9 (3.9 to 6.0) |
| Week 24 | 6.4 (5.2 to 7.5) | 5.1 (4.0 to 6.3) |
| Week 28 | 6.2 (5.1 to 7.3) | 5.6 (4.5 to 6.7) |
| Week 32 | 6.2 (4.9 to 7.4) | 5.1 (3.8 to 6.3) |
| Week 36 | 6.5 (5.3 to 7.7) | 5.5 (4.3 to 6.7) |
| Week 40 | 6.1 (4.9 to 7.4) | 5.1 (3.9 to 6.4) |
| Week 44 | 5.8 (4.5 to 7.1) | 5.1 (3.8 to 6.4) |
| Week 48 | 5.5 (4.1 to 6.9) | 5.2 (3.8 to 6.5) |
| Week 52 | 5.6 (4.2 to 7.1) | 4.5 (3.1 to 5.9) |
| Week 56 | 5.5 (4.1 to 6.9) | 4.7 (3.3 to 6.1) |
| Week 60 | 4.9 (3.5 to 6.3) | 4.7 (3.2 to 6.1) |
| Week 64 | 5.5 (4.1 to 6.9) | 4.8 (3.5 to 6.2) |
| Week 68 | 5.3 (3.9 to 6.8) | 4.6 (3.2 to 6.1) |
| Week 72 | 4.8 (3.3 to 6.3) | 4.0 (2.5 to 5.4) |
| Week 76 | 4.7 (3.1 to 6.2) | 4.4 (2.9 to 5.9) |
| Week 80 | 4.6 (3.1 to 6.1) | 3.5 (2.0 to 5.1) |
| Week 84 | 4.5 (3.0 to 6.1) | 3.5 (2.0 to 5.1) |
| Week 88 | 4.3 (2.7 to 5.9) | 3.7 (2.1 to 5.2) |
| Week 92 | 4.2 (2.6 to 5.9) | 3.7 (2.1 to 5.3) |
| Week 96 | 4.2 (2.5 to 5.8) | 3.7 (2.0 to 5.3) |
| Week 100 | 4.3 (2.7 to 5.9) | 3.6 (2.0 to 5.2) |
| Week 104 | 4.1 (2.5 to 5.8) | 3.6 (2.0 to 5.2) |
| Week 108 | 3.6 (1.8 to 5.3) | 3.2 (1.5 to 4.9) |
| Week 112 | 3.5 (1.8 to 5.2) | 3.1 (1.4 to 4.8) |
BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Gaining ≥15 Letters | 20.0 (15.6 to 24.4) | 15.7 (11.9 to 19.6) |
| Gaining ≥10 Letters | 37.1 (31.7 to 42.4) | 31.7 (26.7 to 36.8) |
| Gaining ≥5 Letters | 59.2 (53.7 to 64.7) | 58.0 (52.6 to 63.5) |
| Gaining ≥0 Letters | 75.6 (70.8 to 80.3) | 76.8 (72.1 to 81.4) |
BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60 | 19.2 (15.0 to 23.5) | 16.6 (12.5 to 20.6) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Week 4 | 10.1 (6.9 to 13.2) | 6.3 (3.8 to 8.8) |
| Week 8 | 13.7 (10.1 to 17.3) | 8.1 (5.3 to 10.9) |
| Week 12 | 16.7 (12.8 to 20.5) | 10.1 (7.0 to 13.1) |
| Week 16 | 17.7 (13.7 to 21.6) | 13.4 (10.0 to 16.9) |
| Week 20 | 19.1 (14.9 to 23.2) | 12.7 (9.1 to 16.2) |
| Week 24 | 22.1 (17.4 to 26.7) | 13.3 (9.6 to 17.0) |
| Week 28 | 20.8 (16.4 to 25.2) | 16.2 (12.1 to 20.3) |
| Week 32 | 21.6 (17.0 to 26.1) | 15.1 (11.3 to 18.9) |
| Week 36 | 21.4 (16.8 to 26.0) | 15.7 (11.8 to 19.6) |
| Week 40 | 22.1 (17.5 to 26.7) | 15.6 (11.7 to 19.5) |
| Week 44 | 22.2 (17.5 to 26.8) | 17.4 (13.2 to 21.6) |
| Week 48 | 21.2 (16.7 to 25.8) | 19.7 (15.3 to 24.0) |
| Week 52 | 22.5 (17.8 to 27.2) | 18.3 (14.0 to 22.7) |
| Week 56 | 23.1 (18.4 to 27.8) | 18.8 (14.6 to 23.0) |
| Week 60 | 21.3 (16.7 to 25.9) | 17.4 (13.3 to 21.5) |
| Week 64 | 20.3 (15.6 to 25.0) | 20.1 (15.7 to 24.6) |
| Week 68 | 23.2 (18.3 to 28.1) | 18.5 (14.1 to 22.8) |
| Week 72 | 21.1 (16.5 to 25.8) | 17.4 (13.1 to 21.6) |
| Week 76 | 22.9 (18.0 to 27.8) | 18.0 (13.7 to 22.3) |
| Week 80 | 19.7 (14.9 to 24.5) | 18.8 (14.4 to 23.2) |
| Week 84 | 21.1 (16.4 to 25.9) | 18.3 (14.0 to 22.5) |
| Week 88 | 24.6 (19.7 to 29.6) | 18.6 (14.3 to 23.0) |
| Week 92 | 21.4 (16.5 to 26.3) | 19.5 (14.9 to 24.0) |
| Week 96 | 23.0 (18.1 to 27.9) | 20.2 (15.7 to 24.6) |
| Week 100 | 21.5 (16.7 to 26.3) | 18.2 (13.9 to 22.5) |
| Week 104 | 22.9 (17.9 to 27.8) | 18.6 (14.2 to 22.9) |
| Week 108 | 21.9 (17.0 to 26.7) | 19.0 (14.6 to 23.4) |
| Week 112 | 24.0 (19.1 to 29.0) | 19.2 (14.6 to 23.7) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Week 4 | 20.1 (16.0 to 24.2) | 16.0 (12.3 to 19.7) |
| Week 8 | 28.6 (23.9 to 33.3) | 25.3 (20.9 to 29.8) |
| Week 12 | 31.4 (26.5 to 36.3) | 30.3 (25.5 to 35.1) |
| Week 16 | 36.9 (31.8 to 41.9) | 31.9 (27.0 to 36.7) |
| Week 20 | 39.1 (34.0 to 44.2) | 30.3 (25.4 to 35.2) |
| Week 24 | 41.4 (36.0 to 46.9) | 34.0 (28.7 to 39.3) |
| Week 28 | 38.9 (33.5 to 44.3) | 34.8 (29.5 to 40.1) |
| Week 32 | 38.6 (33.2 to 44.0) | 32.4 (27.2 to 37.7) |
| Week 36 | 37.1 (31.6 to 42.6) | 34.0 (28.8 to 39.2) |
| Week 40 | 36.9 (31.5 to 42.3) | 33.9 (28.6 to 39.2) |
| Week 44 | 39.5 (33.9 to 45.0) | 34.3 (29.0 to 39.7) |
| Week 48 | 36.8 (31.3 to 42.3) | 36.8 (31.4 to 42.2) |
| Week 52 | 38.7 (33.2 to 44.2) | 37.7 (32.2 to 43.2) |
| Week 56 | 40.3 (34.8 to 45.8) | 36.2 (30.8 to 41.6) |
| Week 60 | 40.1 (34.7 to 45.5) | 34.8 (29.4 to 40.3) |
| Week 64 | 37.2 (31.4 to 43.0) | 36.6 (31.1 to 42.0) |
| Week 68 | 40.0 (34.3 to 45.7) | 33.3 (27.8 to 38.7) |
| Week 72 | 40.1 (34.4 to 45.8) | 34.3 (28.8 to 39.8) |
| Week 76 | 39.4 (33.7 to 45.2) | 33.5 (28.0 to 39.0) |
| Week 80 | 35.5 (29.8 to 41.2) | 33.0 (27.7 to 38.4) |
| Week 84 | 38.2 (32.5 to 43.9) | 34.3 (28.9 to 39.7) |
| Week 88 | 38.9 (33.2 to 44.7) | 33.6 (28.3 to 39.0) |
| Week 92 | 37.8 (31.9 to 43.7) | 35.3 (29.7 to 40.8) |
| Week 96 | 39.6 (33.7 to 45.4) | 35.8 (30.3 to 41.4) |
| Week 100 | 38.5 (32.7 to 44.4) | 36.4 (30.8 to 42.0) |
| Week 104 | 38.7 (32.9 to 44.6) | 38.9 (33.3 to 44.5) |
| Week 108 | 35.1 (29.3 to 40.9) | 36.6 (30.9 to 42.2) |
| Week 112 | 39.5 (33.8 to 45.3) | 34.9 (29.3 to 40.5) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Week 4 | 47.6 (42.3 to 52.8) | 45.6 (40.4 to 50.9) |
| Week 8 | 57.8 (52.5 to 63.0) | 52.3 (47.2 to 57.5) |
| Week 12 | 61.5 (56.3 to 66.8) | 55.0 (49.7 to 60.2) |
| Week 16 | 61.8 (56.5 to 67.0) | 54.0 (48.7 to 59.3) |
| Week 20 | 60.2 (54.8 to 65.6) | 55.5 (50.0 to 60.9) |
| Week 24 | 63.4 (57.9 to 68.9) | 53.6 (48.0 to 59.3) |
| Week 28 | 60.8 (55.3 to 66.3) | 61.4 (55.8 to 67.0) |
| Week 32 | 60.5 (55.1 to 65.9) | 56.4 (50.8 to 62.0) |
| Week 36 | 60.5 (55.0 to 66.0) | 58.5 (53.0 to 64.0) |
| Week 40 | 59.1 (53.6 to 64.6) | 54.5 (48.9 to 60.2) |
| Week 44 | 60.3 (54.7 to 65.9) | 59.0 (53.3 to 64.6) |
| Week 48 | 59.3 (53.7 to 65.0) | 58.8 (53.2 to 64.4) |
| Week 52 | 62.6 (57.0 to 68.1) | 58.5 (52.8 to 64.1) |
| Week 56 | 58.6 (53.0 to 64.2) | 54.4 (48.7 to 60.2) |
| Week 60 | 60.4 (54.8 to 66.0) | 57.4 (51.6 to 63.1) |
| Week 64 | 59.3 (53.5 to 65.2) | 55.1 (49.3 to 60.9) |
| Week 68 | 60.4 (54.7 to 66.1) | 57.0 (51.2 to 62.7) |
| Week 72 | 59.8 (54.0 to 65.5) | 52.3 (46.5 to 58.1) |
| Week 76 | 59.3 (53.5 to 65.1) | 55.0 (49.1 to 60.9) |
| Week 80 | 55.2 (49.3 to 61.2) | 55.5 (49.6 to 61.3) |
| Week 84 | 58.4 (52.6 to 64.2) | 55.6 (49.8 to 61.4) |
| Week 88 | 59.3 (53.5 to 65.1) | 53.8 (48.0 to 59.6) |
| Week 92 | 56.8 (50.8 to 62.9) | 56.0 (50.3 to 61.8) |
| Week 96 | 58.2 (52.2 to 64.1) | 57.5 (51.7 to 63.4) |
| Week 100 | 59.1 (53.2 to 65.1) | 57.1 (51.2 to 63.0) |
| Week 104 | 59.8 (54.0 to 65.7) | 54.8 (48.9 to 60.7) |
| Week 108 | 53.6 (47.7 to 59.6) | 54.1 (48.2 to 60.1) |
| Week 112 | 57.3 (51.4 to 63.2) | 53.5 (47.6 to 59.5) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Week 4 | 78.9 (74.5 to 83.2) | 77.6 (73.3 to 81.9) |
| Week 8 | 80.7 (76.4 to 84.9) | 78.3 (73.9 to 82.7) |
| Week 12 | 84.2 (80.3 to 88.1) | 81.4 (77.3 to 85.6) |
| Week 16 | 84.8 (80.9 to 88.7) | 78.8 (74.6 to 83.1) |
| Week 20 | 80.8 (76.5 to 85.2) | 79.6 (75.2 to 83.9) |
| Week 24 | 81.9 (77.5 to 86.3) | 79.6 (75.1 to 84.1) |
| Week 28 | 77.8 (73.1 to 82.6) | 82.3 (77.9 to 86.7) |
| Week 32 | 78.7 (74.2 to 83.1) | 76.3 (71.5 to 81.0) |
| Week 36 | 78.9 (74.3 to 83.5) | 81.0 (76.6 to 85.4) |
| Week 40 | 77.1 (72.5 to 81.7) | 80.7 (76.3 to 85.2) |
| Week 44 | 77.0 (72.3 to 81.7) | 78.3 (73.6 to 83.0) |
| Week 48 | 77.0 (72.2 to 81.8) | 76.4 (71.5 to 81.3) |
| Week 52 | 77.4 (72.6 to 82.2) | 75.7 (70.7 to 80.6) |
| Week 56 | 76.3 (71.4 to 81.1) | 78.7 (73.9 to 83.5) |
| Week 60 | 74.4 (69.3 to 79.5) | 77.5 (72.6 to 82.3) |
| Week 64 | 77.7 (72.8 to 82.6) | 73.7 (68.6 to 78.8) |
| Week 68 | 74.9 (69.8 to 80.0) | 77.7 (72.8 to 82.6) |
| Week 72 | 74.9 (69.9 to 79.8) | 74.8 (69.8 to 79.8) |
| Week 76 | 75.7 (70.8 to 80.7) | 72.0 (66.6 to 77.4) |
| Week 80 | 75.5 (70.4 to 80.5) | 74.4 (69.3 to 79.5) |
| Week 84 | 75.5 (70.5 to 80.5) | 72.5 (67.3 to 77.7) |
| Week 88 | 74.8 (69.6 to 80.0) | 71.7 (66.4 to 76.9) |
| Week 92 | 75.0 (69.9 to 80.2) | 70.6 (65.3 to 75.9) |
| Week 96 | 74.7 (69.6 to 79.9) | 71.1 (65.7 to 76.5) |
| Week 100 | 74.6 (69.4 to 79.8) | 69.7 (64.2 to 75.2) |
| Week 104 | 73.8 (68.6 to 79.1) | 71.2 (66.0 to 76.5) |
| Week 108 | 73.4 (68.2 to 78.7) | 73.7 (68.4 to 79.0) |
| Week 112 | 72.8 (67.5 to 78.1) | 70.9 (65.5 to 76.3) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Avoiding a Loss of ≥15 Letters | 95.4 (93.0 to 97.7) | 94.1 (91.5 to 96.7) |
| Avoiding a Loss of ≥10 Letters | 91.6 (88.6 to 94.7) | 92.0 (89.1 to 95.0) |
| Avoiding a Loss of ≥5 Letters | 88.0 (84.3 to 91.6) | 86.8 (83.0 to 90.5) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Percentage of Participants Avoiding a Loss of ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60 | 93.9 (91.3 to 96.5) | 94.1 (91.4 to 96.8) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted percentage of participants avoiding a loss of letters in BCVA from baseline was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Week 4 | 97.6 (95.9 to 99.2) | 99.0 (98.0 to 100.0) |
| Week 8 | 97.6 (96.0 to 99.2) | 98.7 (97.6 to 99.9) |
| Week 12 | 98.2 (96.7 to 99.6) | 97.5 (95.8 to 99.1) |
| Week 16 | 98.1 (96.7 to 99.6) | 97.0 (95.3 to 98.8) |
| Week 20 | 97.4 (95.7 to 99.1) | 94.9 (92.5 to 97.3) |
| Week 24 | 97.2 (95.3 to 99.1) | 97.5 (95.8 to 99.3) |
| Week 28 | 95.9 (93.8 to 98.1) | 96.7 (94.6 to 98.8) |
| Week 32 | 95.4 (93.1 to 97.7) | 95.7 (93.5 to 98.0) |
| Week 36 | 95.2 (92.8 to 97.6) | 95.4 (93.1 to 97.7) |
| Week 40 | 96.6 (94.5 to 98.6) | 94.2 (91.6 to 96.8) |
| Week 44 | 95.7 (93.5 to 98.0) | 93.9 (91.2 to 96.6) |
| Week 48 | 94.0 (91.3 to 96.7) | 93.3 (90.4 to 96.1) |
| Week 52 | 93.5 (90.8 to 96.2) | 93.5 (90.7 to 96.3) |
| Week 56 | 94.7 (92.2 to 97.2) | 95.0 (92.5 to 97.5) |
| Week 60 | 93.6 (90.8 to 96.4) | 92.6 (89.7 to 95.6) |
| Week 64 | 94.1 (91.3 to 96.9) | 92.9 (89.9 to 95.9) |
| Week 68 | 92.6 (89.6 to 95.6) | 92.9 (89.9 to 95.8) |
| Week 72 | 93.5 (90.7 to 96.3) | 91.3 (88.2 to 94.4) |
| Week 76 | 94.2 (91.6 to 96.8) | 92.7 (89.8 to 95.7) |
| Week 80 | 93.6 (90.9 to 96.4) | 90.7 (87.4 to 93.9) |
| Week 84 | 92.8 (89.9 to 95.7) | 91.5 (88.4 to 94.5) |
| Week 88 | 93.1 (90.3 to 96.0) | 90.4 (87.2 to 93.7) |
| Week 92 | 92.1 (89.1 to 95.2) | 93.2 (90.5 to 95.9) |
| Week 96 | 91.6 (88.4 to 94.8) | 88.9 (85.3 to 92.5) |
| Week 100 | 92.7 (89.8 to 95.6) | 89.5 (86.0 to 93.0) |
| Week 104 | 93.2 (90.3 to 96.1) | 90.7 (87.4 to 93.9) |
| Week 108 | 92.0 (88.9 to 95.1) | 89.6 (86.0 to 93.2) |
| Week 112 | 90.6 (87.3 to 93.9) | 88.8 (85.1 to 92.4) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted percentage of participants avoiding a loss of letters in BCVA from baseline was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Week 4 | 95.1 (92.9 to 97.4) | 96.2 (94.3 to 98.2) |
| Week 8 | 96.0 (94.0 to 98.0) | 96.9 (95.1 to 98.7) |
| Week 12 | 96.3 (94.4 to 98.3) | 95.5 (93.3 to 97.7) |
| Week 16 | 95.1 (92.8 to 97.4) | 92.6 (89.9 to 95.4) |
| Week 20 | 93.9 (91.3 to 96.5) | 92.7 (89.9 to 95.4) |
| Week 24 | 94.3 (91.7 to 96.9) | 94.4 (91.9 to 96.9) |
| Week 28 | 93.5 (90.8 to 96.2) | 94.9 (92.3 to 97.4) |
| Week 32 | 92.5 (89.6 to 95.3) | 92.9 (89.9 to 95.8) |
| Week 36 | 93.2 (90.3 to 96.0) | 91.7 (88.6 to 94.7) |
| Week 40 | 92.2 (89.2 to 95.2) | 91.8 (88.8 to 94.8) |
| Week 44 | 92.3 (89.4 to 95.3) | 90.9 (87.7 to 94.2) |
| Week 48 | 91.5 (88.3 to 94.6) | 91.5 (88.3 to 94.7) |
| Week 52 | 91.7 (88.6 to 94.7) | 91.1 (87.8 to 94.4) |
| Week 56 | 92.3 (89.3 to 95.3) | 90.4 (87.0 to 93.8) |
| Week 60 | 90.7 (87.5 to 94.0) | 88.5 (85.0 to 92.1) |
| Week 64 | 91.3 (88.0 to 94.6) | 90.3 (87.0 to 93.7) |
| Week 68 | 92.2 (89.2 to 95.3) | 90.3 (86.9 to 93.7) |
| Week 72 | 89.6 (86.2 to 93.1) | 88.1 (84.6 to 91.7) |
| Week 76 | 89.2 (85.6 to 92.7) | 88.0 (84.3 to 91.8) |
| Week 80 | 89.3 (85.7 to 92.9) | 86.4 (82.6 to 90.2) |
| Week 84 | 89.0 (85.5 to 92.5) | 86.9 (83.2 to 90.7) |
| Week 88 | 89.2 (85.7 to 92.7) | 85.2 (81.2 to 89.3) |
| Week 92 | 87.7 (83.8 to 91.6) | 86.3 (82.4 to 90.1) |
| Week 96 | 87.8 (84.0 to 91.5) | 85.7 (81.6 to 89.8) |
| Week 100 | 88.6 (84.9 to 92.3) | 86.1 (82.1 to 90.1) |
| Week 104 | 87.6 (83.7 to 91.5) | 85.3 (81.3 to 89.4) |
| Week 108 | 85.2 (81.1 to 89.4) | 87.3 (83.4 to 91.2) |
| Week 112 | 84.7 (80.5 to 88.9) | 84.2 (79.9 to 88.5) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted percentage of participants avoiding a loss of letters in BCVA from baseline was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Week 4 | 90.5 (87.4 to 93.6) | 90.6 (87.5 to 93.6) |
| Week 8 | 92.3 (89.6 to 95.1) | 90.6 (87.5 to 93.7) |
| Week 12 | 92.2 (89.4 to 95.1) | 88.8 (85.4 to 92.1) |
| Week 16 | 90.4 (87.3 to 93.6) | 87.4 (83.8 to 90.9) |
| Week 20 | 89.3 (85.9 to 92.7) | 87.1 (83.5 to 90.7) |
| Week 24 | 89.1 (85.6 to 92.6) | 88.8 (85.3 to 92.3) |
| Week 28 | 88.2 (84.6 to 91.9) | 90.2 (86.7 to 93.6) |
| Week 32 | 87.0 (83.3 to 90.7) | 85.8 (81.9 to 89.6) |
| Week 36 | 88.3 (84.7 to 91.9) | 86.7 (82.9 to 90.4) |
| Week 40 | 86.8 (83.1 to 90.6) | 87.4 (83.7 to 91.1) |
| Week 44 | 85.2 (81.3 to 89.2) | 85.3 (81.2 to 89.4) |
| Week 48 | 85.6 (81.6 to 89.6) | 83.5 (79.3 to 87.7) |
| Week 52 | 84.8 (80.7 to 88.9) | 85.5 (81.4 to 89.6) |
| Week 56 | 84.4 (80.4 to 88.5) | 83.7 (79.4 to 88.0) |
| Week 60 | 81.5 (77.0 to 85.9) | 84.5 (80.4 to 88.6) |
| Week 64 | 87.8 (84.0 to 91.7) | 85.3 (81.3 to 89.4) |
| Week 68 | 85.0 (80.9 to 89.1) | 87.0 (83.1 to 90.9) |
| Week 72 | 84.2 (80.0 to 88.3) | 81.1 (76.6 to 85.6) |
| Week 76 | 83.5 (79.1 to 87.8) | 83.3 (78.9 to 87.7) |
| Week 80 | 81.0 (76.3 to 85.6) | 81.9 (77.5 to 86.4) |
| Week 84 | 82.6 (78.2 to 86.9) | 81.8 (77.4 to 86.3) |
| Week 88 | 80.8 (76.2 to 85.4) | 78.8 (74.1 to 83.6) |
| Week 92 | 81.7 (77.1 to 86.3) | 79.2 (74.5 to 83.9) |
| Week 96 | 82.1 (77.6 to 86.6) | 78.1 (73.2 to 83.0) |
| Week 100 | 81.7 (77.1 to 86.3) | 80.1 (75.4 to 84.8) |
| Week 104 | 79.6 (74.7 to 84.4) | 80.5 (75.8 to 85.1) |
| Week 108 | 79.7 (74.9 to 84.4) | 80.7 (75.9 to 85.4) |
| Week 112 | 78.6 (73.7 to 83.4) | 78.9 (74.1 to 83.7) |
BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48 | 24.3 (19.5 to 29.1) | 21.3 (16.8 to 25.7) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Week 4 | 11.0 (7.7 to 14.3) | 8.1 (5.3 to 10.9) |
| Week 8 | 16.3 (12.3 to 20.2) | 11.1 (7.8 to 14.4) |
| Week 12 | 20.4 (16.2 to 24.7) | 14.9 (11.2 to 18.6) |
| Week 16 | 20.5 (16.3 to 24.8) | 17.3 (13.4 to 21.3) |
| Week 20 | 22.4 (17.9 to 26.9) | 17.7 (13.5 to 21.8) |
| Week 24 | 25.5 (20.5 to 30.5) | 19.1 (14.7 to 23.4) |
| Week 28 | 25.7 (20.8 to 30.5) | 20.0 (15.5 to 24.5) |
| Week 32 | 27.3 (22.4 to 32.3) | 21.9 (17.3 to 26.5) |
| Week 36 | 27.2 (22.1 to 32.2) | 23.7 (19.0 to 28.4) |
| Week 40 | 26.0 (21.0 to 30.9) | 21.4 (16.8 to 25.9) |
| Week 44 | 26.5 (21.5 to 31.6) | 22.8 (18.1 to 27.5) |
| Week 48 | 24.9 (20.0 to 29.8) | 27.6 (22.5 to 32.6) |
| Week 52 | 25.0 (20.1 to 30.0) | 23.8 (19.0 to 28.7) |
| Week 56 | 26.4 (21.4 to 31.5) | 24.4 (19.7 to 29.1) |
| Week 60 | 25.2 (20.2 to 30.2) | 22.7 (18.1 to 27.4) |
| Week 64 | 24.2 (19.1 to 29.3) | 25.6 (20.6 to 30.5) |
| Week 68 | 27.5 (22.2 to 32.8) | 24.3 (19.4 to 29.2) |
| Week 72 | 26.1 (21.0 to 31.2) | 24.2 (19.4 to 29.0) |
| Week 76 | 27.6 (22.2 to 32.9) | 23.6 (18.8 to 28.5) |
| Week 80 | 24.1 (18.9 to 29.3) | 25.9 (20.9 to 31.0) |
| Week 84 | 26.2 (21.0 to 31.4) | 23.8 (19.0 to 28.7) |
| Week 88 | 29.4 (24.0 to 34.7) | 25.0 (19.9 to 30.0) |
| Week 92 | 27.7 (22.2 to 33.1) | 27.3 (22.1 to 32.6) |
| Week 96 | 28.0 (22.6 to 33.3) | 26.7 (21.7 to 31.8) |
| Week 100 | 27.3 (22.0 to 32.7) | 24.4 (19.5 to 29.3) |
| Week 104 | 27.9 (22.5 to 33.3) | 23.9 (18.9 to 28.8) |
| Week 108 | 27.3 (21.9 to 32.6) | 24.2 (19.3 to 29.1) |
| Week 112 | 26.9 (21.6 to 32.1) | 25.5 (20.4 to 30.6) |
BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (\<69 letters vs. ≥69 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48 | 56.4 (51.5 to 61.4) | 57.0 (51.9 to 62.1) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (\<69 letters vs. ≥69 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Week 4 | 52.8 (48.4 to 57.2) | 50.5 (46.4 to 54.7) |
| Week 8 | 54.5 (49.9 to 59.1) | 50.7 (46.3 to 55.1) |
| Week 12 | 58.3 (53.7 to 62.9) | 53.4 (48.8 to 58.0) |
| Week 16 | 60.4 (55.6 to 65.2) | 53.7 (49.1 to 58.3) |
| Week 20 | 59.5 (54.6 to 64.5) | 54.4 (49.6 to 59.1) |
| Week 24 | 59.4 (54.3 to 64.5) | 54.4 (49.4 to 59.4) |
| Week 28 | 57.5 (52.4 to 62.6) | 59.0 (53.8 to 64.1) |
| Week 32 | 57.7 (52.7 to 62.8) | 58.0 (52.8 to 63.1) |
| Week 36 | 59.7 (54.8 to 64.7) | 59.6 (54.5 to 64.7) |
| Week 40 | 57.5 (52.4 to 62.7) | 58.0 (52.8 to 63.1) |
| Week 44 | 59.9 (54.8 to 65.0) | 59.4 (54.1 to 64.7) |
| Week 48 | 58.9 (53.7 to 64.1) | 58.1 (52.7 to 63.6) |
| Week 52 | 61.0 (55.8 to 66.1) | 57.4 (52.0 to 62.9) |
| Week 56 | 59.0 (53.8 to 64.2) | 55.9 (50.5 to 61.3) |
| Week 60 | 57.9 (52.4 to 63.4) | 56.8 (51.4 to 62.2) |
| Week 64 | 62.5 (57.1 to 67.9) | 57.7 (52.3 to 63.0) |
| Week 68 | 61.0 (55.6 to 66.4) | 59.3 (54.0 to 64.6) |
| Week 72 | 59.5 (54.0 to 65.0) | 57.3 (52.0 to 62.6) |
| Week 76 | 58.4 (52.9 to 63.9) | 55.3 (49.9 to 60.6) |
| Week 80 | 56.8 (51.2 to 62.4) | 55.5 (50.1 to 60.9) |
| Week 84 | 57.6 (52.1 to 63.1) | 58.0 (52.6 to 63.3) |
| Week 88 | 59.1 (53.5 to 64.8) | 54.1 (48.5 to 59.7) |
| Week 92 | 58.6 (52.9 to 64.2) | 57.8 (52.3 to 63.2) |
| Week 96 | 59.3 (53.7 to 64.9) | 58.3 (52.6 to 64.0) |
| Week 100 | 58.1 (52.5 to 63.8) | 57.4 (51.9 to 63.0) |
| Week 104 | 59.8 (54.2 to 65.5) | 58.0 (52.4 to 63.6) |
| Week 108 | 56.4 (50.7 to 62.1) | 56.4 (50.9 to 62.0) |
| Week 112 | 56.3 (50.4 to 62.2) | 54.3 (48.6 to 59.9) |
BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48 | 6.4 (3.7 to 9.1) | 6.9 (4.2 to 9.5) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Week 4 | 5.5 (3.2 to 7.9) | 5.5 (3.2 to 7.7) |
| Week 8 | 5.8 (3.4 to 8.3) | 5.9 (3.6 to 8.2) |
| Week 12 | 4.6 (2.5 to 6.8) | 5.6 (3.3 to 7.9) |
| Week 16 | 5.8 (3.5 to 8.2) | 6.3 (3.9 to 8.8) |
| Week 20 | 5.9 (3.5 to 8.4) | 6.9 (4.3 to 9.5) |
| Week 24 | 4.3 (2.0 to 6.6) | 5.9 (3.4 to 8.5) |
| Week 28 | 5.4 (3.0 to 7.9) | 5.2 (2.8 to 7.7) |
| Week 32 | 6.1 (3.5 to 8.7) | 6.8 (4.2 to 9.4) |
| Week 36 | 6.4 (3.7 to 9.1) | 6.7 (4.1 to 9.3) |
| Week 40 | 7.1 (4.3 to 9.9) | 8.1 (5.3 to 11.0) |
| Week 44 | 7.0 (4.1 to 9.9) | 6.7 (4.0 to 9.3) |
| Week 48 | 7.4 (4.4 to 10.4) | 7.8 (4.9 to 10.7) |
| Week 52 | 8.1 (5.0 to 11.1) | 9.4 (6.3 to 12.6) |
| Week 56 | 6.3 (3.6 to 9.0) | 7.6 (4.7 to 10.5) |
| Week 60 | 6.9 (4.0 to 9.8) | 8.7 (5.6 to 11.7) |
| Week 64 | 7.8 (4.6 to 11.0) | 9.1 (6.0 to 12.3) |
| Week 68 | 7.6 (4.5 to 10.7) | 9.3 (6.2 to 12.5) |
| Week 72 | 8.6 (5.4 to 11.8) | 10.7 (7.5 to 13.9) |
| Week 76 | 7.9 (4.7 to 11.1) | 10.8 (7.5 to 14.2) |
| Week 80 | 8.8 (5.5 to 12.0) | 10.6 (7.2 to 13.9) |
| Week 84 | 7.7 (4.6 to 10.8) | 11.0 (7.8 to 14.2) |
| Week 88 | 9.5 (6.1 to 12.9) | 11.7 (8.3 to 15.0) |
| Week 92 | 9.0 (5.6 to 12.5) | 12.4 (9.0 to 15.7) |
| Week 96 | 8.6 (5.3 to 12.0) | 11.7 (8.2 to 15.1) |
| Week 100 | 8.3 (5.0 to 11.5) | 11.9 (8.4 to 15.4) |
| Week 104 | 9.4 (6.0 to 12.9) | 11.7 (8.3 to 15.1) |
| Week 108 | 7.7 (4.5 to 10.9) | 10.4 (7.1 to 13.7) |
| Week 112 | 8.2 (4.9 to 11.5) | 11.8 (8.3 to 15.2) |
Percentages are based on the number of participants randomized to the faricimab arm who have not discontinued the study at Week 48. The treatment interval at a given visit is defined as the treatment interval decision followed at that visit. The 95% confidence interval (CI) is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab |
|---|---|
| Once Every 8 Weeks | 20.3 (15.9 to 24.8) |
| Once Every 12 Weeks | 34.0 (28.7 to 39.2) |
| Once Every 16 Weeks | 45.7 (40.2 to 51.2) |
Percentages are based on the number of participants randomized to the faricimab arm who have not discontinued the study at Week 60. The treatment interval at a given visit is defined as the treatment interval decision followed at that visit. The 95% confidence interval (CI) is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab |
|---|---|
| Once Every 8 Weeks | 20.2 (15.7 to 24.7) |
| Once Every 12 Weeks | 33.4 (28.1 to 38.8) |
| Once Every 16 Weeks | 46.4 (40.7 to 52.0) |
Percentages are based on the number of participants randomized to the faricimab arm who have not discontinued the study at Week 112. Treatment interval at a given visit is defined as the treatment interval decision followed at that visit. Treatment interval at Week 112 is calculated using data recorded at Week 108. The 95% confidence interval (CI) is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab |
|---|---|
| Once Every 8 Weeks | 25.8 (20.6 to 31.0) |
| Once Every 12 Weeks | 15.1 (10.9 to 19.4) |
| Once Every 16 Weeks | 59.0 (53.2 to 64.9) |
| Injections | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Number of Study Drug Injections Received in the Study Eye Through Week 48 | 6.0 (1 to 8) | 8.0 (1 to 8) |
| Injections | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Number of Study Drug Injections Received in the Study Eye Through Week 60 | 7.0 (1 to 10) | 9.0 (1 to 9) |
| Injections | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Number of Study Drug Injections Received in the Study Eye Through Week 108 | 10.0 (1 to 16) | 15.0 (1 to 15) |
Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. For the Mixed Model of Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (\<33 letters and ≥33 letters), and region (U.S. and Canada, Asia, and the rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.03% CI.
| microns | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Change From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 40, 44, and 48 | -136.8 (-142.6 to -131.0) | -129.4 (-135.2 to -123.5) |
Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. For the Mixed Model of Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (\<33 letters and ≥33 letters), and region (U.S. and Canada, Asia, and the rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.03% CI.
| microns | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Change From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 52, 56, and 60 | -134.5 (-140.5 to -128.6) | -135.5 (-141.5 to -129.6) |
Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. For the Mixed Model of Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (\<33 letters and ≥33 letters), and region (U.S. and Canada, Asia, and the rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.03% CI.
| microns | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Week 4 | -131.7 (-137.9 to -125.4) | -116.3 (-122.5 to -110.1) |
| Week 8 | -142.6 (-148.1 to -137.2) | -131.8 (-137.2 to -126.3) |
| Week 12 | -149.0 (-154.1 to -143.9) | -136.1 (-141.2 to -131.1) |
| Week 16 | -148.7 (-155.1 to -142.3) | -110.4 (-116.8 to -104.0) |
| Week 20 | -132.9 (-139.2 to -126.6) | -136.1 (-142.4 to -129.8) |
| Week 24 | -128.8 (-135.9 to -121.8) | -115.5 (-122.6 to -108.5) |
| Week 28 | -129.1 (-135.5 to -122.8) | -132.5 (-139.0 to -126.1) |
| Week 32 | -142.7 (-150.2 to -135.2) | -114.5 (-122.0 to -107.0) |
| Week 36 | -132.8 (-138.9 to -126.7) | -139.1 (-145.2 to -133.1) |
| Week 40 | -140.8 (-148.0 to -133.7) | -123.9 (-131.0 to -116.7) |
| Week 44 | -133.9 (-139.9 to -128.0) | -142.4 (-148.3 to -136.4) |
| Week 48 | -138.1 (-145.1 to -131.2) | -126.0 (-132.9 to -119.1) |
| Week 52 | -139.9 (-146.2 to -133.6) | -139.6 (-145.9 to -133.3) |
| Week 56 | -140.4 (-147.4 to -133.3) | -125.9 (-133.0 to -118.9) |
| Week 60 | -124.1 (-131.1 to -117.1) | -143.5 (-150.4 to -136.5) |
| Week 64 | -145.4 (-152.4 to -138.4) | -127.8 (-134.7 to -120.9) |
| Week 68 | -137.5 (-144.0 to -130.9) | -142.8 (-149.4 to -136.3) |
| Week 72 | -139.7 (-147.2 to -132.3) | -132.0 (-139.4 to -124.7) |
| Week 76 | -135.3 (-142.2 to -128.3) | -142.8 (-149.8 to -135.9) |
| Week 80 | -146.7 (-154.3 to -139.0) | -132.1 (-139.7 to -124.5) |
| Week 84 | -141.7 (-148.4 to -135.0) | -143.2 (-149.9 to -136.6) |
| Week 88 | -143.9 (-150.7 to -137.2) | -139.3 (-146.0 to -132.6) |
| Week 92 | -144.8 (-151.1 to -138.4) | -148.5 (-154.7 to -142.2) |
| Week 96 | -147.6 (-154.6 to -140.5) | -139.7 (-146.7 to -132.8) |
| Week 100 | -145.7 (-152.7 to -138.7) | -147.1 (-153.9 to -140.2) |
| Week 104 | -147.7 (-154.6 to -140.8) | -143.4 (-150.2 to -136.6) |
| Week 108 | -141.7 (-148.5 to -134.8) | -151.0 (-157.7 to -144.2) |
| Week 112 | -150.1 (-157.1 to -143.1) | -144.3 (-151.3 to -137.4) |
Intraretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 millimetre \[mm\]). The weighted estimates of the percentage of participants with absence of intraretinal fluid were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Week 4 | 89.2 (86.0 to 92.4) | 85.2 (81.6 to 88.8) |
| Week 8 | 87.5 (84.1 to 90.9) | 84.3 (80.6 to 88.1) |
| Week 12 | 89.3 (86.1 to 92.5) | 85.4 (81.8 to 89.0) |
| Week 16 | 89.2 (86.0 to 92.5) | 76.3 (71.8 to 80.8) |
| Week 20 | 82.4 (78.3 to 86.5) | 83.4 (79.5 to 87.3) |
| Week 24 | 80.5 (75.9 to 85.0) | 77.7 (73.0 to 82.4) |
| Week 28 | 76.9 (72.3 to 81.4) | 85.3 (81.3 to 89.2) |
| Week 32 | 86.8 (83.1 to 90.6) | 79.1 (74.6 to 83.7) |
| Week 36 | 79.9 (75.5 to 84.3) | 83.5 (79.4 to 87.6) |
| Week 40 | 82.1 (77.7 to 86.5) | 77.2 (72.5 to 81.9) |
| Week 44 | 75.5 (70.6 to 80.3) | 84.9 (80.7 to 89.1) |
| Week 48 | 82.1 (77.7 to 86.5) | 74.4 (69.4 to 79.5) |
| Week 52 | 83.1 (78.8 to 87.4) | 85.0 (80.9 to 89.1) |
| Week 56 | 84.9 (80.8 to 89.1) | 80.3 (75.8 to 84.9) |
| Week 60 | 72.9 (67.9 to 77.9) | 82.3 (77.9 to 86.7) |
| Week 104 | 80.0 (75.2 to 84.8) | 80.7 (76.1 to 85.4) |
| Week 108 | 77.8 (72.9 to 82.7) | 84.7 (80.5 to 88.9) |
| Week 112 | 82.3 (77.7 to 86.9) | 76.2 (71.0 to 81.3) |
Subretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants with absence of subretinal fluid were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Week 4 | 67.8 (62.9 to 72.7) | 58.8 (53.7 to 64.0) |
| Week 8 | 84.5 (80.6 to 88.4) | 76.4 (71.9 to 81.0) |
| Week 12 | 87.2 (83.6 to 90.8) | 78.5 (74.1 to 82.9) |
| Week 16 | 89.6 (86.3 to 92.9) | 59.9 (54.6 to 65.2) |
| Week 20 | 75.1 (70.3 to 79.9) | 76.3 (71.6 to 81.0) |
| Week 24 | 70.8 (65.6 to 75.9) | 63.9 (58.4 to 69.4) |
| Week 28 | 71.1 (65.9 to 76.2) | 78.8 (74.0 to 83.5) |
| Week 32 | 82.2 (77.9 to 86.5) | 65.1 (59.6 to 70.6) |
| Week 36 | 74.1 (69.2 to 79.1) | 79.9 (75.4 to 84.4) |
| Week 40 | 78.5 (73.9 to 83.1) | 67.3 (61.9 to 72.7) |
| Week 44 | 69.6 (64.3 to 74.9) | 78.0 (73.1 to 82.8) |
| Week 48 | 75.7 (70.7 to 80.8) | 65.8 (60.4 to 71.1) |
| Week 52 | 80.6 (76.0 to 85.2) | 79.9 (75.3 to 84.5) |
| Week 56 | 79.0 (74.3 to 83.7) | 70.1 (64.7 to 75.4) |
| Week 60 | 67.7 (62.2 to 73.2) | 77.5 (72.6 to 82.3) |
| Week 104 | 79.3 (74.5 to 84.2) | 74.9 (69.7 to 80.1) |
| Week 108 | 79.6 (74.6 to 84.6) | 77.4 (72.4 to 82.5) |
| Week 112 | 80.9 (76.1 to 85.7) | 73.1 (67.7 to 78.4) |
Intraretinal fluid and subretinal fluid were measured using optical coherence tomography (OCT) in the central subfield (center 1 millimetre \[mm\]). The weighted estimates of the percentage of participants with absence of intraretinal and subretinal fluid were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Week 4 | 60.8 (55.7 to 66.0) | 49.0 (43.8 to 54.2) |
| Week 8 | 74.5 (69.9 to 79.2) | 63.1 (58.0 to 68.2) |
| Week 12 | 77.4 (72.9 to 81.9) | 66.3 (61.4 to 71.3) |
| Week 16 | 78.8 (74.4 to 83.2) | 44.0 (38.6 to 49.4) |
| Week 20 | 64.7 (59.4 to 70.0) | 62.2 (56.9 to 67.4) |
| Week 24 | 57.2 (51.6 to 62.9) | 48.9 (43.2 to 54.6) |
| Week 28 | 54.8 (49.2 to 60.5) | 66.9 (61.5 to 72.3) |
| Week 32 | 71.9 (66.8 to 77.0) | 51.2 (45.5 to 56.9) |
| Week 36 | 59.4 (53.7 to 65.1) | 66.6 (61.3 to 71.9) |
| Week 40 | 64.8 (59.3 to 70.3) | 52.1 (46.3 to 57.9) |
| Week 44 | 51.4 (45.6 to 57.2) | 65.5 (59.8 to 71.1) |
| Week 48 | 63.3 (57.6 to 68.9) | 47.1 (41.3 to 52.9) |
| Week 52 | 68.4 (63.0 to 73.8) | 68.4 (63.1 to 73.8) |
| Week 56 | 67.8 (62.3 to 73.3) | 55.3 (49.4 to 61.1) |
| Week 60 | 48.6 (42.7 to 54.4) | 62.4 (56.7 to 68.2) |
| Week 104 | 63.0 (57.0 to 68.9) | 59.0 (53.1 to 65.0) |
| Week 108 | 60.7 (54.7 to 66.8) | 63.6 (57.8 to 69.4) |
| Week 112 | 65.9 (60.0 to 71.8) | 54.5 (48.4 to 60.6) |
Pigment epithelial detachment was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants with absence of pigment epithelial detachment were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Week 4 | 5.3 (2.9 to 7.6) | 4.9 (2.6 to 7.2) |
| Week 8 | 3.5 (1.5 to 5.5) | 4.3 (2.1 to 6.5) |
| Week 12 | 2.9 (1.0 to 4.7) | 2.1 (0.6 to 3.7) |
| Week 16 | 1.6 (0.2 to 3.0) | 4.4 (2.2 to 6.6) |
| Week 20 | 2.4 (0.7 to 4.1) | 3.9 (1.8 to 6.1) |
| Week 24 | 3.3 (1.2 to 5.4) | 4.2 (1.9 to 6.6) |
| Week 28 | 2.9 (1.0 to 4.8) | 5.8 (3.1 to 8.5) |
| Week 32 | 3.4 (1.4 to 5.5) | 3.6 (1.4 to 5.7) |
| Week 36 | 4.3 (1.9 to 6.6) | 6.4 (3.7 to 9.2) |
| Week 40 | 7.8 (4.7 to 10.9) | 9.9 (6.5 to 13.3) |
| Week 44 | 3.6 (1.5 to 5.8) | 8.8 (5.5 to 12.2) |
| Week 48 | 3.4 (1.3 to 5.5) | 7.7 (4.6 to 10.7) |
| Week 52 | 2.3 (0.5 to 4.1) | 3.5 (1.4 to 5.7) |
| Week 56 | 2.6 (0.7 to 4.5) | 5.8 (3.0 to 8.5) |
| Week 60 | 4.2 (1.8 to 6.5) | 6.4 (3.6 to 9.2) |
| Week 104 | 3.7 (1.4 to 6.0) | 4.9 (2.3 to 7.6) |
| Week 108 | 3.1 (0.9 to 5.4) | 7.5 (4.2 to 10.7) |
| Week 112 | 4.0 (1.6 to 6.4) | 8.0 (4.7 to 11.2) |
No measurements were reported for this outcome.
The total area of the choroidal neovascularization lesion in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.
| millimetres squared (mm^2) | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Change From Baseline in Total Area of Choroidal Neovascularization Lesion in the Study Eye at Week 48 | 0.0 ± 4.5 | 0.4 ± 4.8 |
The total area of the choroidal neovascularization lesion in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.
| millimetres squared (mm^2) | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Change From Baseline in Total Area of Choroidal Neovascularization Lesion in the Study Eye at Week 112 | 1.2 ± 4.6 | 1.6 ± 5.0 |
The total area of choroidal neovascularization leakage in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.
| millimetres squared (mm^2) | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Change From Baseline in Total Area of Choroidal Neovascularization Leakage in the Study Eye at Week 48 | -3.8 ± 6.9 | -3.0 ± 6.9 |
The total area of choroidal neovascularization leakage in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.
| millimetres squared (mm^2) | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Change From Baseline in Total Area of Choroidal Neovascularization Leakage in the Study Eye at Week 112 | -5.4 ± 5.7 | -5.0 ± 6.4 |
This analysis of adverse events (AEs) includes both ocular and non-ocular (systemic) AEs. Multiple occurrences of the same AE in one individual are counted only once. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. AEs of special interest included the following: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law; Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).
| Percentage of participants | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Adverse Event (AE) | 88.3 | 89.3 |
| Serious AE (SAE) | 24.0 | 27.7 |
| AE Leading to Withdrawal from Study Treatment | 3.6 | 2.7 |
| AE of Special Interest (AESI) | 4.8 | 6.8 |
This analysis of adverse events (AEs) only includes ocular AEs, which are categorized as having occurred either in the study eye or the fellow eye. Multiple occurrences of the same AE in one individual are counted only once. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. Ocular AEs of special interest included the following: Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).
| Percentage of participants | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Study Eye: Adverse Event (AE) | 55.0 | 56.5 |
| Study Eye: Serious AE (SAE) | 4.2 | 3.9 |
| Study Eye: AE Leading to Withdrawal from Treatment | 1.8 | 0.6 |
| Study Eye: Treatment-related AE | 4.2 | 2.7 |
| Study Eye: Treatment-related SAE | 1.2 | 0.0 |
| Study Eye: AE of Special Interest (AESI) | 3.6 | 3.9 |
| Study Eye: AESI, Drop in VA Score ≥30 Letters | 2.7 | 3.0 |
| Study Eye: AESI, Associated with Severe IOI | 0.3 | 0.3 |
| Study Eye: AESI, Intervention Req. to Prevent Permanent Vision Loss | 0.6 | 0.6 |
| Fellow Eye: AE | 39.3 | 44.3 |
| Fellow Eye: SAE | 1.2 | 3.3 |
| Fellow Eye: AESI | 1.2 | 3.0 |
| Fellow Eye: AESI, Drop in VA Score ≥30 Letters | 0.9 | 2.1 |
| Fellow Eye: AESI, Intervention Req. to Prevent Permanent Vision Loss | 0.3 | 0.9 |
This analysis of adverse events (AEs) only includes non-ocular (systemic) AEs. Multiple occurrences of the same AE in one individual are counted only once. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. The non-ocular AE of special interest was: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.
| Percentage of participants | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Adverse Event (AE) | 75.7 | 72.9 |
| Serious AE (SAE) | 19.8 | 22.6 |
| AE Leading to Withdrawal from Study Treatment | 1.8 | 2.1 |
| AE of Special Interest (AESI) | 0.0 | 0.3 |
Faricimab concentration in plasma was determined using a validated immunoassay method.
| micrograms per millilitre (μg/mL) | Arm A: Faricimab |
|---|---|
| Baseline | 0.0000 ± 0.0005 |
| Week 4 | 0.0288 ± 0.0194 |
| Week 16 | 0.0337 ± 0.0266 |
| Week 20 | 0.0044 ± 0.0062 |
| Week 48 | 0.0139 ± 0.0175 |
| Week 76 | 0.0057 ± 0.0109 |
| Week 112 | 0.0099 ± 0.0140 |
Anti-drug antibodies (ADAs) against fariciamb were detected in plasma using a validated bridging enzyme-linked immunosorbent assay (ELISA). The percentage of participants with treatment-emergent ADA-positive samples includes post-baseline evaluable participants with at least one treatment-induced (defined as having an ADA-negative sample or missing sample at baseline and any positive post-baseline sample) or treatment-boosted (defined as having an ADA-positive sample at baseline and any positive post-baseline sample with a titer that is equal to or greater than 4-fold baseline titer) ADA-positive sample during the study treatment period.
| Percentage of participants | Arm A: Faricimab |
|---|---|
| Total Treatment-Emergent ADA-Positive | 11.5 |
| Treatment-Induced ADA-Positive | 11.2 |
| Treatment-Boosted ADA-Positive | 0.3 |
Collected over From first dose of study drug through end of study (up to 112 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Faricimab | 13/333 (3.9%) | 80/333 (24%) | 211/333 (63.4%) |
| Arm B: Aflibercept | 7/336 (2.1%) | 93/336 (27.7%) | 200/336 (59.5%) |
| Event | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Neovascular age-related macular degenerationEye disorders | 1/333 | 9/336 |
| PneumoniaInfections and infestations | 6/333 | 5/336 |
| Atrial fibrillationCardiac disorders | 5/333 | 4/336 |
| COVID-19Infections and infestations | 5/333 | 4/336 |
| CataractEye disorders | 2/333 | 5/336 |
| Cardiac failure congestiveCardiac disorders | 3/333 | 1/336 |
| EndophthalmitisInfections and infestations | 3/333 | 0/336 |
| Femur fractureInjury, poisoning and procedural complications | 1/333 | 3/336 |
| DehydrationMetabolism and nutrition disorders | 0/333 | 3/336 |
| DizzinessNervous system disorders | 0/333 | 3/336 |
| Event | Arm A: Faricimab | Arm B: Aflibercept |
|---|---|---|
| Neovascular age-related macular degenerationEye disorders | 65/333 | 63/336 |
| Conjunctival haemorrhageEye disorders | 36/333 | 33/336 |
| CataractEye disorders | 27/333 | 36/336 |
| NasopharyngitisInfections and infestations | 23/333 | 35/336 |
| Urinary tract infectionInfections and infestations | 26/333 | 23/336 |
| HypertensionVascular disorders | 24/333 | 13/336 |
| Dry eyeEye disorders | 18/333 | 24/336 |
| Vitreous floatersEye disorders | 23/333 | 12/336 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 22/333 | 19/336 |
| Vitreous detachmentEye disorders | 19/333 | 21/336 |
Intent-to-Treat (ITT) Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization.
| Age, Continuous(Years) | Arm A: Faricimab | Arm B: Aflibercept | Total |
|---|---|---|---|
| Mean | 75.9 ± 8.6 | 76.7 ± 8.8 | 76.3 ± 8.7 |
| Sex: Female, Male(Participants) | Arm A: Faricimab | Arm B: Aflibercept | Total |
|---|---|---|---|
| Female | 191 | 211 | 402 |
| Male | 143 | 126 | 269 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Faricimab | Arm B: Aflibercept | Total |
|---|---|---|---|
| Hispanic or Latino | 26 | 26 | 52 |
| Not Hispanic or Latino | 303 | 308 | 611 |
| Unknown or Not Reported | 5 | 3 | 8 |
| Race/Ethnicity, Customized(Participants) | Arm A: Faricimab | Arm B: Aflibercept | Total |
|---|---|---|---|
| White | 303 | 302 | 605 |
| Asian | 26 | 28 | 54 |
| Black or African American | 0 | 3 | 3 |
| American Indian or Alaska Native | 1 | 2 | 3 |
| Multiple | 1 | 0 | 1 |
| Unknown | 3 | 2 | 5 |
| Region of Enrollment(Participants) | Arm A: Faricimab | Arm B: Aflibercept | Total |
|---|---|---|---|
| United States and Canada | 182 | 184 | 366 |
| Asia | 26 | 26 | 52 |
| Rest of the World | 126 | 127 | 253 |
| Number of Participants by the Eye (Right or Left) Chosen as the Study Eye(Participants) | Arm A: Faricimab | Arm B: Aflibercept | Total |
|---|---|---|---|
| Right Eye | 166 | 178 | 344 |
| Left Eye | 168 | 159 | 327 |
| Best Corrected Visual Acuity (BCVA) Letter Score in the Study Eye(ETDRS Letters) | Arm A: Faricimab | Arm B: Aflibercept | Total |
|---|---|---|---|
| Mean | 61.3 ± 12.5 | 61.5 ± 12.9 | 61.4 ± 12.7 |
| Number of Participants by the BCVA Letter Score Categories in the Study Eye(Participants) | Arm A: Faricimab | Arm B: Aflibercept | Total |
|---|---|---|---|
| ≥74 Letters | 47 | 52 | 99 |
| 73 to 55 Letters | 200 | 201 | 401 |
| ≤54 Letters | 87 | 84 | 171 |
2 further baseline measures are reported on the registry.
Showing the first 100 of 161 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Feb 2019 to primary completion in Oct 2020, 20 months.
Results were first posted in May 2022, 1 year 6 months after primary completion. A results delay was requested in Sep 2021.
Of 16 phase 3 interventional studies under Wet Macular Degeneration, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 50. This study's 20 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Faricimab